Schwab Charles Investment Management Inc. increased its stake in shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) by 6.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 618,589 shares of the biotechnology company’s stock after purchasing an additional 38,440 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.44% of ZIOPHARM Oncology worth $3,799,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Amalgamated Bank grew its stake in shares of ZIOPHARM Oncology by 12.9% during the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,924 shares during the period. Oppenheimer & Co. Inc. grew its stake in shares of ZIOPHARM Oncology by 50.0% during the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 6,000 shares during the period. Adell Harriman & Carpenter Inc. acquired a new stake in shares of ZIOPHARM Oncology during the third quarter worth $141,000. Principal Financial Group Inc. grew its stake in shares of ZIOPHARM Oncology by 7.5% during the second quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,673 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ZIOPHARM Oncology by 933.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,918 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 32,444 shares during the period. 40.23% of the stock is owned by institutional investors and hedge funds.
In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper bought 6,440 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the completion of the purchase, the chief executive officer now owns 1,083,731 shares in the company, valued at $5,071,861.08. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 10.40% of the stock is currently owned by insiders.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) opened at $4.36 on Friday. ZIOPHARM Oncology Inc. has a 52 week low of $3.77 and a 52 week high of $7.88. The stock has a market capitalization of $604.76, a PE ratio of -8.38 and a beta of 1.44.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The business had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. During the same period in the previous year, the firm posted ($0.11) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. equities research analysts anticipate that ZIOPHARM Oncology Inc. will post -0.54 EPS for the current fiscal year.
ZIOP has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $9.50 price objective on shares of ZIOPHARM Oncology in a research note on Tuesday, November 7th. Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Friday, November 10th. Raymond James Financial reaffirmed a “hold” rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. ValuEngine cut ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Finally, BidaskClub raised ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. ZIOPHARM Oncology currently has an average rating of “Hold” and an average price target of $12.67.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/14/schwab-charles-investment-management-inc-purchases-38440-shares-of-ziopharm-oncology-inc-ziop.html.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP).
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.